Drug Trial Radar · NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Jul 23, 2024
Primary completion
Oct 31, 2031
Study completion Oct 31, 2032
Sponsor
- Lead sponsor
- Fred Hutchinson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cord Blood Network
- First posted
- Aug 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.
Conditions
- Acute Leukemia of Ambiguous Lineage
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Hematopoietic and Lymphatic System Neoplasm
- Mixed Phenotype Acute Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirateProcedure
Undergo bone marrow aspirate
CyclophosphamideDrug
Given IV
CyclosporineDrug
Given IV or PO
Diagnostic Imaging TestingProcedure
Undergo diagnostic imaging
Echocardiography TestProcedure
Undergo ECHO
Fludarabine PhosphateDrug
Given IV
Multigated Acquisition ScanProcedure
Undergo MUGA
Mycophenolate MofetilDrug
Given IV
Survey AdministrationOther
Ancillary studies
ThiotepaDrug
Given IV
Total-Body IrradiationRadiation
Undergo high-dose or middle-intensity TBI
Umbilical Cord Blood TransplantationProcedure
Undergo UCBT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: At 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.